Cure8 trial brief
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
Clinicians; researchers focused on IBD biomarkers; adult patients interested in noninvasive tests for disease monitoring
This is a registry record for a completed observational study (planned enrollment 338) at Showa Inan General Hospital in Japan. Investigators collected serum samples and performed colonoscopy with histology within 7 days to compare LRG levels with Mayo endoscopy scores for UC and CDAI for CD. The primary measured outcome was serum LRG.
The design is observational and cross-sectional around colonoscopy timing; it assesses association, not treatment effects. The record excludes patients with other major comorbidities (eg, other autoimmune diseases, severe organ failure, cancer, infections).
This is an observational clinicaltrials.gov record (completed) describing methods and outcomes but the supplied text does not include study results or performance measures, so no conclusions about LRG accuracy can be drawn from this record alone.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD have a higher lifetime risk of colorectal cancer; updated UK guidelines give clinicians and patients evidence-based recommendations on when and how to do surveillance colonoscopy to detect precancerous...
Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies...
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
